Capital Insight Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,177
Closed -$1.26M 62
2025
Q4
$1.26M Buy
1,177
+413
+54% +$395K 0.27% 75
2025
Q3
$583K Sell
764
-235
-24% -$175K 0.1% 125
2025
Q2
$779K Sell
999
-19
-2% -$14.8K 0.14% 108
2025
Q1
$841K Sell
1,018
-406
-29% -$338K 0.15% 104
2024
Q4
$1.1M Hold
1,424
0.19% 89
2024
Q3
$1.26M Sell
1,424
-90
-6% -$80.9K 0.22% 87
2024
Q2
$1.37M Sell
1,514
-75
-5% -$60K 0.26% 81
2024
Q1
$1.24M Sell
1,589
-259
-14% -$184K 0.23% 86
2023
Q4
$1.08M Sell
1,848
-315
-15% -$184K 0.22% 88
2023
Q3
$1.16M Sell
2,163
-125
-5% -$64.4K 0.26% 84
2023
Q2
$1.07M Sell
2,288
-628
-22% -$263K 0.24% 87
2023
Q1
$1M Buy
2,916
+795
+37% +$268K 0.24% 94
2022
Q4
$776K Sell
2,121
-140
-6% -$49.6K 0.2% 97
2022
Q3
$731K Sell
2,261
-150
-6% -$47.5K 0.2% 97
2022
Q2
$782K Hold
2,411
0.18% 105
2022
Q1
$690K Hold
2,411
0.14% 119
2021
Q4
$666K Sell
2,411
-190
-7% -$48.2K 0.14% 122
2021
Q3
$601K Sell
2,601
-190
-7% -$46.9K 0.13% 124
2021
Q2
$641K Sell
2,791
-312
-10% -$62.7K 0.14% 121
2021
Q1
$580K Buy
+3,103
New +$607K 0.14% 122

Other funds holding LLY

Capital Insight Partners's LLY Position: Q1 2026 in Review

Capital Insight Partners sold out of Eli Lilly (LLY) in Q1 2026, closing a stake of 1,177 shares — an estimated $1.26M sold.

Capital Insight Partners first reported a position in LLY in Q1 2021 and held it in 20 quarters. The position peaked at $1.37M in Q2 2024. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Capital Insight Partners reported no remaining Eli Lilly position as of Q1 2026 after selling out during the quarter.
  • Capital Insight Partners sold 1,177 Eli Lilly shares in Q1 2026, an estimated $1.26M.
  • Capital Insight Partners first reported a position in Eli Lilly in Q1 2021 and held it in 20 quarters.
  • Capital Insight Partners's Eli Lilly position peaked at $1.37M in Q2 2024.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Capital Insight Partners's 13F filing for Q1 2026.